Brief: Citius Pharmaceuticals Announces Efficacy And Safety Data For Its I/Ontak (E7777) Phase 3 Study
09/11/2022 14:34
Nov 9 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS ANNOUNCES EFFICACY AND SAFETY DATA
FOR
ITS I/ONTAK (E7777) PHASE 3 STUDY FOR TREATMENT OF CUTANEOUS
T-CELL LYMPHOMA TO BE PRESENTED AT THE 64TH AMERICAN SOCIETY OF
HEMATOLOGY (ASH) ANNUAL MEETING
Source text for Eikon: ID:nPn5gMR3Ka
Further company coverage: CTXR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules